The Role of Artificial Intelligence in Revolutionizing Endometriosis Diagnosis and Clinical Pathology: A Commentary Review of New Biomarkers (2020–2026)

In: Biomedical Journal of Scientific & Technical Research · 2026 · vol. 66(3) · doi:10.26717/bjstr.2026.66.010350 · W7204939195
OA: diamond CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-19 ⓘ

This review synthesizes 2020–2026 research demonstrating that AI-driven analysis of miRNA signatures and protein panels achieves high-accuracy non-invasive diagnosis of endometriosis, potentially replacing invasive surgical laparoscopy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-06 · read from full text ⓘ

This commentary review synthesizes research from 2020 to 2026 on using artificial intelligence and machine learning to develop non-invasive diagnostic tools for endometriosis. The authors highlight that AI models, particularly those utilizing microRNA signatures from blood or saliva, have achieved high accuracy in distinguishing patients with the condition from healthy controls, potentially reducing the long diagnostic delays associated with surgical laparoscopy. While these technologies offer promise for molecular stratification and precision medicine, the paper notes significant limitations including a lack of large-scale clinical validation, data heterogeneity, and challenges in standardizing biomarker protocols. This paper is centrally about endometriosis — specifically focusing on novel AI-driven diagnostic biomarkers and their potential to replace or augment surgical diagnosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The diagnosis of endometriosis has historically been hampered by an average diagnostic delay of seven to ten years, owing largely to the field's reliance on invasive surgical laparoscopy as the "gold standard."The integration of artificial intelligence (AI) and machine learning (ML) into clinical pathology, however, is now catalyzing a paradigm shift toward non-invasive, precision diagnostics.This report synthesizes research published between 2020 and 2026, highlighting the emergence of high-accuracy diagnostic tools built on microRNA (miRNA) signatures, plasma protein panels, and genomic markers.Key findings include the validation of blood-and saliva-based miRNA signatures achieving area under the curve (AUC) values exceeding 0.95, rivaling the accuracy of surgical diagnosis.AI methodologies including Random Forest, eXtreme Gradient Boosting (XGBoost), and support vector machines (SVM) have identified novel biomarkers such as PNMA2, LRP1, and WISP2/CCN5.These advances promise not only to shorten diagnostic latency but also to enable molecular stratification, supporting more personalized treatment strategies.Challenges remain in clinical standardization and in validating certain protein-based models, yet the accumulated evidence suggests that AI-driven clinical pathology will soon augment and in some cases replace traditional surgical diagnosis for many patients.
Full text 21,796 characters · extracted from oa-pdf · 5 sections · click to expand

Abstract

The diagnosis of endometriosis has historically been hampered by an average diagnostic delay of seven to ten years, owing largely to the field’s reliance on invasive surgical laparoscopy as the “gold standard.” The integra - tion of artificial intelligence (AI) and machine learning (ML) into clinical pathology, however, is now catalyzing a paradigm shift toward non-invasive, precision diagnostics. This report synthesizes research published between 2020 and 2026, highlighting the emergence of high-accuracy diagnostic tools built on microRNA (miRNA) sig - natures, plasma protein panels, and genomic markers. Key findings include the validation of blood- and sali - va-based miRNA signatures achieving area under the curve (AUC) values exceeding 0.95, rivaling the accuracy of surgical diagnosis. AI methodologies including Random Forest, eXtreme Gradient Boosting (XGBoost), and sup- port vector machines (SVM) have identified novel biomarkers such as PNMA2, LRP1, and WISP2/CCN5. These advances promise not only to shorten diagnostic latency but also to enable molecular stratification, supporting more personalized treatment strategies. Challenges remain in clinical standardization and in validating certain protein-based models, yet the accumulated evidence suggests that AI-driven clinical pathology will soon aug - ment and in some cases replace traditional surgical diagnosis for many patients. Abbreviations: AI: Artificial Intelligence; ML: Machine Learning; miRNA: microRNA; AUC: Area Under the Curve; SVM: Support Vector Machines; ANN: Artificial Neural Networks; CNN: Convolutional Neural Networks; WGCNA: Weighted Gene Co-Expression Network Analysis ARTICLE INFO Received: August 07, 2026 Published: August 19, 2026 Citation: Raouf Roshdy and Reham A Rashed. The Role of Artificial Intel - ligence in Revolutionizing Endome - triosis Diagnosis and Clinical Pathol - ogy: A Commentary Review of New Biomarkers (2020–2026) . Biomed J Sci & Tech Res 66(3)-2026. BJSTR. MS.ID.010350.

Introduction

Endometriosis is a complex, multifactorial inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects millions of individuals worldwide and is a leading cause of chronic pelvic pain and infertility [1]. Despite this prevalence, the current diagnostic framework remains significantly flawed: laparoscopy an invasive surgical procedure carrying real risks and high costs remains the only definitive diagnostic method [2,3]. This reliance on surgery contributes to substantial diagnostic delays and prolonged patient suffering. Clinical pathology is now undergo - ing a transformation driven by artificial intelligence. By leveraging large multi-omics datasets (transcriptomics, proteomics, methylom - ics) alongside high-resolution imaging, AI-based tools are uncovering patterns “crimson clues,” in the words of one recent review within peripheral blood, saliva, and tissue that are invisible to the human eye [4,5]. These technologies aim to shift endometriosis diagnosis away from a purely symptom-based or surgical approach and toward one grounded in precision medicine and molecular stratification [3,5]. This report examines the AI methodologies, novel biomarkers, and clinical impacts described in the recent literature, with the goal of providing a comprehensive overview of the current state of the art. AI Methodologies and Approaches in the Sources The literature reviewed here reveals a diverse array of AI and machine learning methodologies, each tailored to a particular type of biological data. Broadly, these approaches fall into two categories: supervised learning for classification, and unsupervised learning for subtype identification. Copyright@ : Raouf Roshdy | Biomed J Sci & Tech Res | BJSTR.MS.ID.010350. Volume 66- Issue 3 DOI: 10.26717/BJSTR.2026.66.010350 58791 Supervised Learning and Ensemble Methods The most common application of AI in the sources reviewed is supervised learning used to differentiate patients with endometriosis from healthy controls. • Ensemble classifiers : “GenomeForest” is an advanced en - semble machine learning classifier that uses chromosomal partitioning to analyze transcriptomic and methylomic data, achieving F1 scores as high as 0.968 [6]. • Tree-based models : Random Forest, XGBoost, and Ada - Boost are frequently favored for their robustness in handling high-dimensional omics data. Random Forest algorithms, for example, have been used to validate salivary miRNA signa - tures with 96.2% sensitivity [7] and to identify driver bio - markers from RNA-seq data [8]. • Neural networks: Artificial neural networks (ANN) and con - volutional neural networks (CNN) are increasingly applied to complex diagnostic models and imaging data [8,9]. Integrated Discovery Pipelines Many studies rely on hybrid pipelines that combine bioinformat - ics with machine learning for biomarker screening. • WGCNA and ML: Weighted gene co-expression network anal- ysis (WGCNA) is often paired with machine learning to iden - tify lipid metabolism-related biomarkers and molecular sub - types [10]. • Multi-omics integration: Markov et al. describe the integra - tion of ML and deep learning with imaging, molecular bio - markers, and histopathology to build multi-omics diagnostic pathways [11]. • Stacked models: Stacked machine learning models have been developed to distinguish endometriosis from adenomyosis us- ing peripheral blood and coagulation data [12]. Findings and Comparative Analysis The synthesis of recent research points to several high-potential biomarker categories, with miRNA signatures currently showing the greatest diagnostic accuracy. miRNA Signatures and Non-Invasive Diagnostics MicroRNAs have emerged as the most promising candidates for non-invasive testing. • Blood-based signatures: Bendifallah et al. [13] developed an 86-miRNA signature using algorithms such as Random Forest and XGBoost, achieving an AUC of 0.984 [13] a robust, repro - ducible diagnostic that could potentially replace laparoscopy [13]. • Saliva-based testing: A 109-miRNA saliva signature has been validated with 96.2% sensitivity and 95.1% specificity [7]. This approach offers a genuinely non-invasive alternative that could be administered in a primary care setting, meaningfully shortening the path to diagnosis [14]. • Early-stage detection : Specific miRNA panels (e.g., miR- 199a, miR-122) combined with CA-125 have demonstrated an AUC of 0.939 for detecting early-stage disease [15]. Proteomic and Immunologic Biomarkers While miRNAs dominate the literature, protein- and im - mune-based markers offer critical insight into disease pathophysiol - ogy. • Plasma protein panels: Schoeman et al. [16] identified a pan- el of 10 plasma protein biomarkers. Using a Random Forest model, they achieved an AUC of 0.997 for severe endometrio- sis, though accuracy for milder cases was considerably lower (Model 2 AUC = 0.729) [16]. • Immune screening : Non-invasive immune screening tests combined with ML (logistic regression) have identified mark- ers predictive of disease, including IL-10 in Tc cells, reduced NK cytotoxic activity, and CXCL1 [2]. • Challenges in reproducibility: Notably, Fishman [17] found that some cytokine-based ML models performed no better than chance, underscoring the need for rigorous standardiza- tion in protein-based discovery [17]. Genomic and Transcriptomic Drivers Machine learning has also proven instrumental in identifying the molecular drivers underlying the disease. • Hub genes : Integrated identification methods have pointed to five key diagnostic genes FOS, EPHX1, DLGAP5, PCSK5, and ADAT1 [18]. A separate study identified LRP1 as a potential diagnostic and immunomodulatory target, showing a strong correlation with M2 macrophage infiltration [19]. • Novel biomarkers : AI-driven screening has highlighted PNMA2 (linked to malignant growth and anti-apoptosis) [20], WISP2/CCN5 (a potential early-screening marker) [21], and SPP1 (a modulator of macrophage polarization) [22]. • Cuproptosis-related genes : ML algorithms have identified genes such as GLS and PDHA1 as being associated with endo - metriosis progression and immune infiltration [23]. AI in Imaging and Digital Pathology AI’s impact extends to the visual characterization of the disease as well. Copyright@ : Raouf Roshdy | Biomed J Sci & Tech Res | BJSTR.MS.ID.010350. 58792 Volume 66- Issue 3 DOI: 10.26717/BJSTR.2026.66.010350 • Automated recognition : Proof-of-concept studies have demonstrated the automatic visual recognition of endometri- osis lesions during laparoscopy using AI, a step that could help standardize surgical assessment [24]. • Tissue segmentation: AI-based tissue segmentation and cell identification in histological sections for instance, identifying CD138+ cells are improving the precision of pathological diag- nosis in infertility-associated conditions [25,26]. • Imaging integration: Deep learning models are increasing - ly being integrated with ultrasound and MRI data to improve detection of deep infiltrating endometriosis and ovarian endo- metriomas [27,28]. Impact on Clinical Pathology and Diagnostic Workflows The integration of AI into clinical pathology is reshaping the diag- nostic landscape in several ways: • Reducing diagnostic latency : By enabling high-accuracy blood or saliva tests, AI tools can identify candidate biomark - er genes and signatures that shorten the years-long wait many patients face for a diagnosis [6,21]. • Molecular stratification: AI enables identification of disease subtypes, moving the field away from a one-size-fits-all ap - proach and toward models informed by molecular, epidemio- logic, and cell-specific data [5]. • Precision medicine : The development of diagnostic mod - els that predict treatment response for example, PNMA2 as a therapeutic target is helping guide more personalized thera - peutic strategies [3,20]. • Augmenting the gold standard: While some sources suggest AI could ultimately replace laparoscopy [13,15], others view it instead as a powerful complement that improves the effi - ciency and accuracy of existing histopathological and surgical workflows [18,29,30].

Limitations

of the Evidence Despite rapid progress in the field, several limitations must be acknowledged: • Validation gaps : Many of the biomarkers identified so far remain in the discovery or interim-validation stage [4,14]. Large-scale, multi-center prospective trials will be necessary to confirm their clinical utility. • Data heterogeneity: AI model performance varies consider - ably depending on the dataset and disease stage, as reflected in the gap between severe- and mild-endometriosis detection in protein-based models [16]. • Interpretability and fallibility : The “black box” nature of some ML models remains a challenge in diagnostic patholo - gy, where clinical decisions demand transparent reasoning [31,32]. • Standardization: Standardized protocols for biomarker col - lection and processing are urgently needed to ensure that AI-driven findings remain reproducible across different clin - ical settings [4]. Research Gaps and Future Directions Future research in this area should focus on: • Longitudinal studies: Understanding how AI-identified bio - markers change over the course of the disease and in response to treatment. • Integration with clinical data : Combining molecular signa - tures with symptom clustering and imaging data to build a holistic diagnostic “score” [33]. • Cost-effectiveness analysis: Evaluating the economic impact of replacing laparoscopy with AI-driven non-invasive tests. • Pathologist training : Developing educational frameworks that help pathologists integrate AI assistance into daily prac - tice [34].

Conclusion

Artificial intelligence is no longer a peripheral technology in the study of endometriosis it is the engine driving the next generation of clinical pathology. Through the identification of highly accurate miR- NA signatures, novel genomic drivers such as LRP1 and PNMA2, and the automation of digital pathology, AI is supplying the tools needed to overcome the field’s historical challenges of delayed diagnosis and invasive surgery. Rigorous clinical validation remains the final hur - dle, but the evidence accumulated between 2020 and 2026 strongly suggests that AI-powered non-invasive diagnostics will soon become a cornerstone of endometriosis management, ushering in an era of precision medicine for millions of patients..

References

1. A Ashish, K Kusum, S Rai, R Singh (2020) Endometriosis a brief review: evaluation of crucial risk factors and current treatment regimes. Interna - tional Journal of Advances in Medicine 7(12): 1896-1905. 2. N Attia, M Franzoi, M P McHale, A R Gargiulo, M S Abrão, et al. (2023) Iden- tification of immunologic predictive biomarkers of endometriosis using a non-invasive immune screening test in association with machine learning modeling. Fertility and Sterility 120(4): e226-e227. 3. L N Onah, M N Ezenwaeze, C N Nwankwo (2026) Endometriosis: From delayed diagnosis to precision medicine. International Journal of Science and Research Archive 18(1): 306-314. 4. T Gibbons, N Rahmioglu, K T Zondervan, C M Becker (2024) Crimson Copyright@ : Raouf Roshdy | Biomed J Sci & Tech Res | BJSTR.MS.ID.010350. Volume 66- Issue 3 DOI: 10.26717/BJSTR.2026.66.010350 58793 clues: advancing endometriosis detection and management with novel blood biomarkers. Fertility and Sterility 121(2): 145-163. 5. C R Nezhat, Tomiko T Oskotsky, Joshua F R, Susan J F, Angie T , et al. (2025) Real World Perspectives on Endometriosis Disease Phenotyping Through Surgery, Omics, Health Data, and Artificial Intelligence. npj Women’s Health 3(1): 8. 6. S Akter, D Xu, S C Nagel, J J Bromfield, K E Pelch, et al. (2020) GenomeFor- est: An Ensemble Machine Learning Classifier for Endometriosis, p. 33-42. 7. S Bendifallah, Y Dabi, S Suisse, L Delbos, A Spiers, et al. (2023) Validation of a Salivary miRNA Signature of Endometriosis — Interim Data. NEJM Evidence 2(7). 8. Zhen G, T Chu, J She, S Chen, P Wang, et al. (2026) Exploration of driver biomarkers and immune microenvironment in patients with endometri - osis: Evidence from RNA-seq and machine learning. Journal of Reproduc - tive Immunology 175: 104872. 9. H Malvezzi, E B Marengo, S Podgaec, C de A Piccinato (2020) Endometri - osis: current challenges in modeling a multifactorial disease of unknown etiology. Journal of Translational Medicine 18(1): 1-21. 10. Y Guo, Y Hou, J Wu, N Lou, D Yang, et al. (2025) Identification and Subtype Analysis of Lipid Metabolism-Related Diagnostic Biomarkers for Endo - metriosis Based on WGCNA and Machine Learning. American Journal of Reproductive Immunology, p. 94. 11. D Markov, J Gurung, U Khalid, K Bechev, V Aleksiev, et al. (2026) Emerging Pathways to Non-Invasive Diagnosis in Endometriosis: Integrating Ma - chine Learning, Deep Learning and Multi-Omics Biomarkers. Diagnostics 16(12): 1823. 12. W Wang, W Zeng, S Yang (2024) A stacked machine learning-based clas - sification model for endometriosis and adenomyosis: a retrospective co - hort study utilizing peripheral blood and coagulation markers. Frontiers in Digital Health 6: 1463419. 13. S Bendifallah, Y Dabi, S Suisse, L Jornea, D Bouteiller, et al. (2022) MicroR- Nome analysis generates a blood-based signature for endometriosis. Sci - entific Reports 12(1). 14. Gaia-Oltean AI, Boitor D, Laura-Ancuta P , Geanina G, Teodora T , et al. (2025) Non-Invasive Methods for Early Diagnosis of Endometriosis-A Comprehensive Narrative Literature Review. Healthcare (Basel, Switzer - land) 13(24): 3276. 15. M K Gałuszka, K K Figurny, P P Jagodziński, A Pławski (2025) Potential biomarkers for early detection of endometriosis: current state of art (what we know so far). Journal of Applied Genetics. 16. E M Schoeman, S Bringans, K Peters, T Casey, C Andronis, et al. (2024) Identification of plasma protein biomarkers for endometriosis and the de- velopment of statistical models for disease diagnosis. Human Reproduc - tion 40(2): 270-279. 17. D Fishman (2022) Developing a data analysis pipeline for automated pro- tein profiling in immunology. 18. H Zhang, H Zhang, H Yang, A N Shuid, D Sandai, et al. (2023) Machine learning-based integrated identification of predictive combined diagnos - tic biomarkers for endometriosis. Frontiers in Genetics 14: 1290036. 19. Xie Liu (2026) LRP1 as a potential diagnostic and immunomodulatory tar- get in endometriosis: evidence from multi-omics and single-cell analyses. Frontiers in Immunology p: 17. 20. Mengjun Zhang, Zidi Zhang, Jialin Wang, Haodi Yue, Xueling Lou, et al. (2025) Unveiling the Role of PNMA2 in Endometriosis: From Proliferation and Apoptosis to Immunomodulation. Journal of Cellular and Molecular Medicine 29(9): e70576. 21. Sheng Dou, Shaohua Ling, Weihua Nong, Bixiao Wei, Yuehua Huang, et al. (2025) WISP2/CCN5 revealed as a potential diagnostic biomarker for endometriosis based on machine learning and single-cell transcriptomic analysis. Functional & Integrative Genomics 25(1): 131. 22. Sijia Zhang, Yi Yang, Chen Zhang, Xiaoyao Che, Fawei Li, et al. (2025) SPP1 as a key modulator of M2 macrophage polarization promotes endometri - osis progression via activation of the FAK/PI3K/AKT pathway: A bioinfor- matics and experimental study. International Immunopharmacology 166: 115563. 23. Y Lu, J Wang, G Sun, Z Fang, Z Xing, et al. (2023) Machine learning algo - rithms for a novel cuproptosis-related gene signature of diagnostic and immune infiltration in endometriosis. Scientific Reports 13(1): 21603. 24. A Netter, S Noorzadeh, F Duchateau, H Abrao, J Desternes, et al. (2025) Ini- tial results in the automatic visual recognition of endometriosis lesions by artificial intelligence during laparoscopy: a proof-of-concept study. Jour - nal of Minimally Invasive Gynecology 32(12): 1118-1125. 25. S E Korman, G Vissers, M A J Gorris, K Verrijp (2024) Artificial intel - ligence-based tissue segmentation and cell identification in multi - plex-stained histological endometriosis sections. Human Reproduction 40(3): 450-460. 26. S Lee, R K Arffman, E K Komsi, O Lindgren, J A Kemppainen, et al. (2024) AI-algorithm training and validation for identification of endometrial CD138+ cells in infertility-associated conditions; polycystic ovary syn - drome (PCOS) and recurrent implantation failure (RIF). Journal of Pathol- ogy Informatics 15: 100380-100380. 27. N Jiang, H Xie, J Lin, Y Wang, Y Yin, et al. (2022) Diagnosis and Nursing Intervention of Gynecological Ovarian Endometriosis with Magnetic Res - onance Imaging under Artificial Intelligence Algorithm. Computational Intelligence and Neuroscience, p. 1-10. 28. J Avery, A Deslandes, S M Freger, M Leonardi, G Lo, et al. (2023) Non-inva- sive Diagnostic Imaging for Endometriosis Part 1: A Systematic review of recent developments in Ultrasound. Combination Imaging and Artificial Intelligence. Fertility and Sterility 121(2): 164-188. 29. Y Yu, W Hing W, Y Hu, Y Shen, X Xu, et al. (2025) Translation of miRNA blood-based discovery to molecular testing for clinical diagnosis of endo- metriosis. medRxiv. 30. M J Iqbal, Z Javed, H Sadia, I A Qureshi, A Irshad, et al. (2021) Clinical appli- cations of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell International 21(1): 270-270. 31. P Mishra, A Panda, M Mahapatra, P Dakshinakabat, A Mohanty, et al. (2024) Application and fallibility of Artificial Intelligence and machine learning in Diagnostic Pathology. Bangladesh Journal of Medical Science 23(10): S32-S37. 32. J H Harrison, John R Gilbertson, M G Hanna, N H Olson, J N Seheult, et al. (2021) Introduction to Artificial Intelligence and Machine Learning for Pathology. Archives of Pathology & Laboratory Medicine 145(10): 1228- 1254. 33. S M Mouazen, S Khan, N S Farag (2025) Machine learning in the early de - tection of endometriosis: a literature review on symptom clustering and imaging integration. Precision and Future Medicine 9(3): 117-128. 34. Z Ahmad, S Rahim, M Zubair, J A Ghafar (2021) Artificial intelligence (AI) in medicine, current applications and future role with special emphasis on its potential and promise in pathology: present and future impact, ob - stacles including costs and acceptance among pathologists, practical and philosophical considerations. A comprehensive review. Diagnostic Pathol- ogy 16(1): 24-24. Copyright@ : Raouf Roshdy | Biomed J Sci & Tech Res | BJSTR.MS.ID.010350. 58794 Volume 66- Issue 3 DOI: 10.26717/BJSTR.2026.66.010350 Submission Link: https://biomedres.us/submit-manuscript.php Assets of Publishing with us • Global archiving of articles • Immediate, unrestricted online access • Rigorous Peer Review Process • Authors Retain Copyrights • Unique DOI for all articles https://biomedres.us/ This work is licensed under Creative Commons Attribution 4.0 License ISSN: 2574-1241 DOI: 10.26717/BJSTR.2026.66.010350 Raouf Roshdy . Biomed J Sci & Tech Res

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-pdf ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Source provenance

openalex
last seen: 2026-11-18T06:02:33.299327+00:00
License: CC0 · commercial use OK